Igm Biosciences, INC Form 4 insider transactions

Chris H. Takimoto, Chief Medical Officer of IGM Biosciences, sold 1,487 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Misbah Tahir, CFO of IGM Biosciences, sold 1,487 shares of common stock on September 13, 2024, to cover tax withholding obligations related to vesting restricted stock units.

IGM Biosciences CEO Fred Schwarzer sold 3,946 shares of common stock on September 13, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Bruce Keyt, Chief Scientific Officer of IGM Biosciences, sold 1,487 shares of common stock on September 13, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Mary Beth Harler, Head of Research & Autoimmunity at IGM Biosciences, sold 1,487 shares of common stock to cover tax withholding obligations.

Lisa Decker, Chief Business Officer of IGM Biosciences, sold 925 shares of common stock on September 13, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Director William Strohl of IGM Biosciences received 125,000 restricted stock units (RSUs) on August 8, 2024, which vest over time based on continued service.

Director Julie Hambleton exercised stock options and sold shares of IGM Biosciences under a pre-arranged Rule 10b5-1 trading plan.

Chief Medical Officer Chris H. Takimoto of IGM Biosciences received restricted stock units (RSUs) in exchange for cancelled stock options, according to a recent SEC filing.

IGM Biosciences' CFO, Misbah Tahir, reports the acquisition and disposal of restricted stock units (RSUs) and stock options as part of an option exchange program.

Bruce Keyt, Chief Scientific Officer of IGM Biosciences, reports changes in beneficial ownership due to an option exchange program, resulting in the acquisition of restricted stock units (RSUs) and cancellation of stock options.

Mary Beth Harler, Head of Research & Autoimmunity at IGM Biosciences, reports transactions involving restricted stock units (RSUs) and stock options.

Lisa Lynn Decker, Chief Business Officer of IGM Biosciences, reports transactions involving restricted stock units and stock options, including an option exchange program.

Redmile Group, a significant shareholder in IGM Biosciences, reports acquiring additional shares as part of director compensation.

Michael Lee, a director at IGM Biosciences, acquired 1,734 shares of common stock as a quarterly retainer, while holding shares on behalf of Redmile Group, LLC.

Jakob Haldor Topsoe, a director of IGM Biosciences, acquired 1,734 shares of common stock as part of the company's Outside Director Compensation Policy.

Christina Teng Topsoe, a director of IGM Biosciences, reports acquiring shares through vested restricted stock units and indirect holdings.

Director Elizabeth Thompson acquired 1,452 shares of IGM Biosciences common stock as part of a quarterly retainer payment.

Director Kathleen Behrens reports acquisition of 3,078 shares of IGM Biosciences common stock and disposal of 13,124 shares.

Baker Bros. Advisors LP reports changes in beneficial ownership of IGM Biosciences stock due to the issuance of restricted stock units (RSUs) in lieu of director retainer fees.

Steven Weber, Principal Accounting Officer of IGM Biosciences, sold 495 shares of common stock on June 14, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Chris H. Takimoto, Chief Medical Officer of IGM Biosciences, reports acquiring shares through an employee stock purchase plan and selling shares to cover tax obligations.

Misbah Tahir, CFO of IGM Biosciences, sold 1,570 shares of common stock on June 14, 2024, to cover tax withholding obligations related to vesting restricted stock units.

IGM Biosciences CEO Fred Schwarzer reports acquiring shares through an employee stock purchase plan and selling shares to cover tax obligations.

Bruce Keyt, Chief Scientific Officer of IGM Biosciences, reports the acquisition and disposition of company stock, including purchases under the employee stock purchase plan and sales to cover tax obligations.

Mary Beth Harler, Head of Research & Autoimmunity at IGM Biosciences, sold 1,570 shares of common stock to cover tax withholding obligations.

Lisa Decker, Chief Business Officer of IGM Biosciences, sold 977 shares of common stock on June 14, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Director Michael Lee of IGM Biosciences receives 1,734 shares of common stock as a quarterly retainer, while disclaiming beneficial ownership due to his role as a Redmile Group representative.

Director Jakob Haldor Topsoe receives 1,734 shares of IGM Biosciences common stock as a quarterly retainer, while Topsoe Holding A/S indirectly holds a significant stake.

Director Christina Teng Topsoe reports acquisition of IGM Biosciences common stock through restricted stock units and indirect holdings.